A groundbreaking project led by The GCI’s Michel L. Tremblay, Ph.D., and McGill University’s David Langlais, Ph.D., secures significant funding from Genome Canada. The initiative focuses on enhancing cancer immunotherapy by harnessing Natural Killer (NK) cells, aiming to develop a potent, pharmacologically activated NK cell bank for widespread cancer treatment, potentially revolutionizing patient care. Read more.